FluLaval® Quadrivalent

BIOLOGICAL3 trials

Sponsors

GlaxoSmithKline

Conditions

Influenza

Phase 2

Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age

CompletedNCT01974895

GlaxoSmithKlineInfluenza

Start: 2013-10-23End: 2014-07-03Updated: 2018-09-07

Phase 3

A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Children

CompletedNCT01218308

GlaxoSmithKlineInfluenza

Start: 2010-12-09End: 2012-01-09Updated: 2018-08-01

A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older

CompletedNCT01440387

GlaxoSmithKlineInfluenza

Start: 2011-09-30End: 2011-10-22Updated: 2018-09-07

Related Papers

Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine in US Children 6-35 Months of Age During 2013-2014: Results From A Phase II Randomized Trial.

2015-07-1623 citations

A historically-controlled Phase III study in adults to characterize the acceptability of a process change for manufacturing inactivated quadrivalent influenza vaccine.

2014-03-105 citations

Vaccine for Prevention of Mild and Moderate-to-Severe Influenza in Children

New England Journal of Medicine2013-12-11139 citations